Feeds:
Posts
Comments

Review of HTMS Technologies for In Vitro ADMET Profiling

March 18, 2010 by Vaughn P. Miller

This month, Shou and Zhang published a very comprehensive and detailed review of the recent developments in high-throughput mass spec-based analysis for in vitro ADMET assays [Shou, W.Z. & J. Zhang, Recent Development in High-Throughput Bioanalytical Support for In Vitro ADMET Profiling, Expert Opin. Drug Metabo. Toxicol. (2010), 6(3), 321-336. http://www.ncbi.nlm.nih.gov/pubmed/20163321].

The authors start by clearly defining the challenges faced by pharmaceutical bioanalytical groups that support these assays – large volumes of samples and expectations for very fast data turn-around times.  The authors then provide a thorough review of 1) advances in more conventional LC-MS/MS bioanalytical approaches and 2) emerging technologies and approaches using novel sample introduction methods, new ionization sources or alternative mass analyzers. The advantages and disadvantages of all of the technologies and methods described are succinctly summarized and referenced (there are 165 literature references).  Finally, the authors conclude by giving their opinion on the strongest technologies, which they utilize in their own laboratory, and then speculate on the near future adoption of high resolution mass spectrometers.  I strongly recommend this paper to anyone working in the in vitro ADMET field who is concerned with increasing the throughput and efficiency of these assays.

Posted in In The News, Research | Tagged , , , | Leave a Comment »

BIOCIUS to Re-Broadcast Webinar!

March 4, 2010 by BIOCIUS Life Sciences

Vaughn Miller will present his talk a second time for those who missed it, or may have been unable to attend due to time differences.

Increasing the Speed and Efficiency of ADME Screening Assays Using Mass Spec Technology
Join us for a Webinar on March 16
Space is limited.
Reserve your Webinar seat now at:
https://www1.gotomeeting.com/register/717139513
Pharmaceutical companies and biotechs alike have many strong incentives to increase the speed and efficiencies of their drug discovery and development processes.

Register for this 30 minute webinar, and you’ll learn:

• How you can increase the efficiency of drug discovery and “Do more with less”,
• How to reduce sample backlog and increase speed to results.
• New techniques for high throughput in vitro ADME screening, and how they fit into existing worklfows
• How you can take advantage of the improved selectivity of mass spec devices

Case studies of pharmaceuticals and biotechs will be discussed too. You’ll hear how some organizations have been able to increase efficiency while utilizing existing staff, instrument, and assay resources.

Who should attend?
People who work in laboratories that support Lead Discovery, High-throughput Screening, ADME programs and therapeutic target areas of oncology, metabolic disorders, epigenetics, cardiovascular disease, anti-infectives, neurology and inflammation.
Title: Increasing the Speed and Efficiency of ADME Screening Assays Using Mass Spec Technology
Date: Tuesday, March 16, 2010
Time: 9:00 AM – 10:00 AM EDT
After registering you will receive a confirmation email containing information about joining the Webinar.
System Requirements
PC-based attendees
Required: Windows® 2000, XP Home, XP Pro, 2003 Server, Vista
Macintosh®-based attendees
Required: Mac OS® X 10.4 (Tiger®) or newer

Posted in Uncategorized | Leave a Comment »

Join us for a Webinar!

February 22, 2010 by BIOCIUS Life Sciences

Increasing the Speed and Efficiency of
ADME Screening Assays Using Mass Spec Technology
Thursday, February 25
11:30am EST
Space is limited.
Reserve your Webinar Seat Now at:
https://www1.gotomeeting.com/register/902678520
Pharmaceutical companies and biotechs alike have many strong incentives to increase the speed and efficiencies of their drug discovery and development processes. During this free 30 minute webinar you will learn:

• How you can increase the efficiency of drug discovery and “Do more with less”
• How to reduce sample backlog and increase speed to results.
• New techniques for high throughput in vitro ADME screening, and how they fit into existing worklfows
• How you can take advantage of the improved selectivity of mass spec devices

Case studies of pharmaceuticals and biotechs will be discussed too. You’ll hear how some organizations have been able to increase efficiency while utilizing existing staff, instrument, and assay resources.

Who should attend? People who work in laboratories that support Lead Discovery, High-throughput Screening, ADME programs and therapeutic target areas of oncology, metabolic disorders, epigenetics, cardiovascular disease, anti-infectives, neurology and inflammation.

Speaker: Vaughn P. Miller, Ph. D, BIOCIUS Life Sciences
Title: “Increasing the Speed and Efficiency of ADME Screening Assays
Using Mass Spec Technology”
Date: Thursday, February 25, 2010
Time: 11:30 AM – 12:15 PM EST
System Requirements
PC-based attendees
Required: Windows® 2000, XP Home, XP Pro, 2003 Server, Vista
Macintosh®-based attendees
Required: Mac OS® X 10.4 (Tiger®) or newer
BIOCIUS. Faster Answers.

RapidFire® technology is described in patent numbers 6,932,939, 6,812,030 7,100,460, 7,588,725,

Posted in Events | Leave a Comment »

BIOCIUS to attend California Analytical Chemists Organization Event on Friday Februray 19th!

February 16, 2010 by BIOCIUS Life Sciences

On Friday February 19th, BIOCIUS will be one of the vendors at local C.A.C.O meeting in Foster City, CA.  The Event will be held at the Foster City Crowne Plaza from 11 a.m. – 1:30 p.m.  Stop by if you are in the area!

https://www.caco-ca.org/aspx/sfchemists.aspx

Posted in Events | Leave a Comment »

BIOCIUS Sponsored Pond Hockey Team Wins the Title!

February 10, 2010 by BIOCIUS Life Sciences

BIOCIUS employees, Margaret Chute, Production Associate(furthest left in picture) and Marissa Mullane, Marketing Assistant(furthest right in picture) spent a long weekend in Rangeley, Maine playing in the New England Pond Hockey Festival.

Originally an all-male tournament, the New England Pond Hockey Tournament opened up a women’s division for the first time this year, and like most of the athletically active BIOCIUS employees, Margaret and Marissa were eager to spend a weekend facing off against old college rivals of Bowdoin College.  Both Margaret and Marissa played hockey for Colby College in their college days, before working for BIOCIUS Life Sciences.

After three games on Saturday(two wins and a loss to Bowdoin), in just above zero degree weather, the Blueskis geared up for the championship game on Sunday.  After another hard fought game, the BIOCIUS Bogart Blueskis came out on top and took the Tournament title earning the first women’s spot on the championship trophy.

Colby, Bowdoin Rivalry

Posted in Events | Leave a Comment »

BIOCIUS Life Sciences to Attend Lab Automation 2010 Conference

January 18, 2010 by BIOCIUS Life Sciences

The conference will be held January 23-27, 2010 at the Palm Springs Convention Center, in Palm Springs, CA.  Be sure to stop by the BIOCIUS booth at ALA, # 368!

In addition to attending ALA, BIOCIUS Senior Field Applications Engineer, Maxine Jonas will be presenting a talk: “The RapidFire 300: An integrated, automated SPE-MS system for high-throughput ADME sample analysis” in the High-Throughput Technologies track in the session titled “Parallel Process Advances”.  The talk will take place on Wednesday January 27th at 9:00 a.m.

Posted in Uncategorized | Leave a Comment »

Interesting perspective on future directions of high-throughput screening

January 11, 2010 by Lauren Frick

Mayr and Bojanic’s noteworthy recent article gives a descriptive history of HTS, starting with its origins and detailing the path through which it has evolved over the past decade and a half to encompass multiple steps such as the primary, counter, and validation screens that are currently familiar.  The authors describe how researchers’ focus has shifted over time from a brute-force effort at simply increasing throughput to a more narrow approach geared toward achieving better data on fewer compounds by employing in silico tools, focused libraries, and fragment-based screens.  They go on to forecast future alterations in the target classes of major interest as well as both the screen design and infrastructure used by companies to meet their pressing need to acquire high quality data on a large number of compounds rapidly and with minimal artifacts, such that those compounds with greatest promise of becoming viable drugs are identified as quickly and efficiently as possible.  I, for one, am certainly looking forward to discovering how accurate the authors’ predictions turn out to be as the field continues to advance!

Posted in In The News | Tagged , , | Leave a Comment »

Happy Holidays From BIOCIUS!

December 24, 2009 by BIOCIUS Life Sciences

In the spirit of holiday giving, this year we decided to Adopt a family for the holidays!

Our family has three children: Annalisa (age 3), Amari (age 2), and Mario (8 months).  Their mother requested items such as pajamas, warm weather clothing, toys, and books.

BIOCIUS employees were very generous, either employees shopped for items, or donated money, and  Scientist Michelle Romm did the rest of the shopping!

We have much to be thankful for as a company this holiday season, and are happy to share our blessings with those less fortunate in the community!

HAPPY HOLIDAYS!

Posted in Events | Leave a Comment »

BIOCIUS Life Sciences forms Independent Operating Company

December 16, 2009 by BIOCIUS Life Sciences

BIOCIUS Life Sciences forms Independent Operating Company

RapidFire® Business Unit completes strategic spin‐out from BioTrove Inc.

Woburn, MA. December 16, 2009. BIOCIUS Life Sciences announced today that it has completed its spin‐out from BioTrove Inc. and is an independent operating company. BIOCIUS Life Sciences holds all of the RapidFire® intellectual property and technology; most importantly every employee of the former BioTrove RapidFire business unit is now a member of BIOCIUS Life Sciences.

BIOCIUS is supported by a syndicate of investors that includes Catalyst Health Ventures, Excel Venture Management, Fletcher‐Spaght, CB Health Ventures, Vox Equity Partners, Echelon Ventures and BioFrontier Partners. Led by Chairman and Chief Executive Officer Jeffrey Leathe, the BIOCIUS team of experienced scientists and engineers will now be able to focus their resources on the RapidFire product line as well as new research and development projects committed to eliminating bottlenecks in drug discovery for their clients and collaborators. According to Mr. Leathe, “BIOCIUS is well capitalized and we plan to maximize on our strengths in drug discovery products and services to aggressively expand our portfolio and add value to our many collaborators in the pharma and biotech community. The current and future customer base will benefit from the shared vision and innovative solutions of our expansive pipeline.”

Joining Mr. Leathe, are corporate officers Dr. Can ‘Jon’ Özbal, COO and Mr. Gary St. Pierre, CFO who will lead an experienced executive team with a history of success in the biotech and pharmaceutical market. Building on a breakout year in 2009 for sales of RapidFire instruments and services, BIOCIUS plans to continue its concentration on the application areas of in vitro ADME and lead discovery, with its industry‐leading, label‐free platform. According to Dr. Can ‘Jon’ Özbal, “new products in the pipeline will both enhance the workflows of our existing pharma and biotech customers, and allow us to expand that customer base with technologies also suited to our clients at academic and government institutions.”

About RapidFire® Technology

RapidFire mass spectrometry greatly decreases the bottlenecks that occur during drug discovery. By enabling automated sample preparation at a rate of up to six seconds per sample and integrating seamlessly to the mass spectrometer, RapidFire enhances high‐throughput screening of candidate drug compounds and in vitro ADME assays. RapidFire allows for the analysis of a wide range of otherwise intractable targets such as triglycerides, lipids, fatty acids, prostaglandins, steroids, coenzyme A derivatives, neurotransmitters, epigenetic targets, anti‐fungals and anti‐infectives, which are difficult to study using traditional methods such as fluorescence or radiolabels. RapidFire hardware is available as a solution in our collaborators laboratories or as a contract research service in the BIOCIUS laboratory.

About BIOCIUS Life Sciences, Inc.

Named from the Greek word “BIO” (life) and the Latin word “OCIUS” (faster), BIOCIUS Life Sciences, provides the biopharmaceutical industry with faster answers: Products and services committed to speed and accuracy in drug discovery. Used by 13 of the top 15 pharmaceutical companies, BIOCIUS’s products and contract research services enable our partners to exceed their business goals.

Contact:
Jennifer M. Rossi, PhD
Director of Marketing & Corporate Communications
781.721.3679
jrossi@BIOCIUS.com

Posted in In The News | Leave a Comment »

Check Out What’s Happening in the BIOCIUS lab

December 8, 2009 by BIOCIUS Life Sciences

BIOCIUS Lab Video 1

BIOCIUS Lab Video 1

This movie requires Adobe Flash for playback.

A normal day in the BIOCIUS lab- team members Nik Parikh (foreground), Peter Rye and Lauren Frick are setting up reaction plates to investigate enzyme kinetics and CYP450 Inhibition.

Posted in Research | Leave a Comment »

« Newer Posts - Older Posts »